<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03091738</url>
  </required_header>
  <id_info>
    <org_study_id>HM13968</org_study_id>
    <secondary_id>5R01DK087913</secondary_id>
    <nct_id>NCT03091738</nct_id>
  </id_info>
  <brief_title>Ramelteon for Treatment of Insomnia in Cirrhosis</brief_title>
  <official_title>Ramelteon for Treatment of Insomnia in Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effect of ramelteon, a melatonin receptor agonist, on sleep quality, duration&#xD;
      and cognitive function in cirrhotics with insomnia.&#xD;
&#xD;
      Patients with cirrhosis have difficulties with their sleep quality, which adversely affects&#xD;
      their health-related quality of life. It is assumed the sleep disturbances are related to&#xD;
      hepatic encephalopathy (HE) in these patients. However, several recent reports have indicated&#xD;
      that this is not a perfect concordance and that cognition is not related to sleep&#xD;
      disturbance. The mechanism for this change is not clear, although there is evidence of&#xD;
      melatonin-delayed phase in these patients as well as difficulties with the excretion pattern&#xD;
      of cortisol. Ghrelin is an orexigenic hormone produced by the stomach which stimulates the&#xD;
      appetite and also has a profound effect on sleep. Our group has demonstrated a substantial&#xD;
      alteration in ghrelin secretion in cirrhosis that correlates with poor slow-wave sleep. In&#xD;
      healthy individuals, ghrelin injection encourages slow-wave sleep while sleep deprivation&#xD;
      increases ghrelin levels. The role of ghrelin in the sleep disturbances of cirrhosis has not&#xD;
      been determined. Prior studies have also lacked the use of overnight polysomnography as a&#xD;
      tool and have relied on either actigraphy or questionnaires. There is a need for detailed&#xD;
      mechanistic and therapeutic approaches to analyzing sleep disturbances in cirrhosis.&#xD;
&#xD;
      Also the therapy of sleep disturbance in cirrhosis is largely empirical. Prior studies have&#xD;
      evaluated hydroxyzine which runs the risk of precipitating HE. Ramelteon is a melatonin&#xD;
      analog that is FDA-approved for use in insomnia and will potentially be useful to restore the&#xD;
      sleep-wake cycle in cirrhosis-associated sleep disturbance.&#xD;
&#xD;
      The investigators aim to study the impact of the FDA-approved ramelteon on the sleep quality&#xD;
      (using questionnaires and sleep diaries) on these patients with cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a prospective study of patients with compensated cirrhosis This study will&#xD;
      be divided into screening and post-ramelteon visits.&#xD;
&#xD;
      For this study, subjects with cirrhosis will be recruited from the hepatology clinic.&#xD;
&#xD;
      Screening: All subjects will come for an initial screening visit to the CRSU at which point&#xD;
      the following procedures will be performed:&#xD;
&#xD;
        1. Vitals, including BMI&#xD;
&#xD;
        2. Neck circumference&#xD;
&#xD;
        3. Skinfold thickness and waist-hip ratio&#xD;
&#xD;
        4. Beck Depression Inventory (BDI)&#xD;
&#xD;
        5. Sickness impact profile for overall HRQOL&#xD;
&#xD;
      Questionnaires regarding sleep:&#xD;
&#xD;
        1. Berlin questionnaire&#xD;
&#xD;
        2. STOP Bang questionnaire&#xD;
&#xD;
        3. Epworth sleepiness scale (ESS) and&#xD;
&#xD;
        4. Pittsburgh sleep quality index (PQSI)&#xD;
&#xD;
      Cirrhotic patients with either of the criteria below (a) neck circumference &gt;17 inches for&#xD;
      men and &gt;16 inches for women (b) Positive Berlin questionnaire will be excluded because these&#xD;
      are highly suggestive of sleep disturbances and OSA. The investigators will also exclude&#xD;
      patients who have evidence of moderate to severe depression on Beck Depression Inventory&#xD;
      (score â‰¥20) without the suicide question.&#xD;
&#xD;
      All enrolled study participants will perform 5 paper-pencil and two computerized tests of&#xD;
      intelligence which will last approximately 35 minutes total.&#xD;
&#xD;
      RAMELTEON THERAPY:&#xD;
&#xD;
      The subjects' study chart, current medications, medical history and pregnancy testing will be&#xD;
      assessed by sleep physicians at VCU, who will then decide if this patient would benefit from&#xD;
      ramelteon.&#xD;
&#xD;
      The criteria used will be insomnia along with the absence of OSA by the questionnaires.&#xD;
      Ramelteon is an FDA-approved selective melatonin receptor 1 and 2 analog indicated for use in&#xD;
      insomnia. The dose used will be 8 mg, the lowest possible dose. If the sleep specialists&#xD;
      believe that a particular cirrhotic patient is a candidate for this therapy, they will be&#xD;
      clinically prescribed ramelteon after a detailed face to face visit explaining the risks and&#xD;
      benefits. Ramelteon is not indicated in patients with severe hepatic impairment (defined as&#xD;
      Child Class C), therefore, these patients will not be included in this study.&#xD;
&#xD;
      If the patient agrees to take the medicine, it will be dispensed through the investigational&#xD;
      pharmacy, where it will be stored for this study. Patients will be asked to complete a&#xD;
      medication and sleep diary for the duration of the drug therapy which will be a maximum of 15&#xD;
      days. Within 15 days of drug initiation, the patients will be asked to complete the sleep&#xD;
      questionnaires again and cognitive testing similar to that described in visit 1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Actual">October 1, 2018</completion_date>
  <primary_completion_date type="Actual">October 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sleep Quality Evaluation</measure>
    <time_frame>14 days</time_frame>
    <description>Pittsburgh Sleep Quality Index (PSQI) is a 19 item survey measuring 7 components of sleep. Component scores are summed to yield a global PSQI score. Scores range from 0 to 21 with higher scores indicate worse sleep quality.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daytime Sleepiness Evaluation</measure>
    <time_frame>14 days</time_frame>
    <description>Epworth Sleepiness Scale asks participants to rate (on a scale of 0 to 3) their likelihood of falling asleep during 8 daily activities. Scores range from 0 to 24 with lower scores indicating less sleepiness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sickness Impact Profile</measure>
    <time_frame>14 days</time_frame>
    <description>Sickness Impact Profile is a 68 question assessment. Items are scored 0 (no) or 1 (yes). Scores range from 0 to 68 with higher numbers indicating worse quality of life.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Ramelteon Pill</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients given ramelteon and re-evaluated after 15 days of therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramelteon Pill</intervention_name>
    <description>Patients with compensated cirrhosis and insomnia will be provided ramelteon</description>
    <arm_group_label>Ramelteon Pill</arm_group_label>
    <other_name>Ramelteon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Child class A cirrhosis proven by biopsy, radiology or endoscopic evidence of varices&#xD;
             - Able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient unwilling to start therapy&#xD;
&#xD;
          -  Allergic reactions to ramelteon in the past&#xD;
&#xD;
          -  Obstructive sleep apnea&#xD;
&#xD;
          -  Periodic limb movement disorder&#xD;
&#xD;
          -  Moderate to severe depression&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
&#xD;
          -  Night shift workers&#xD;
&#xD;
          -  Inter-continental travel within the last 4 weeks&#xD;
&#xD;
          -  Renal insufficiency on dialysis&#xD;
&#xD;
          -  Current alcohol or illicit drug use&#xD;
&#xD;
          -  Diabetes Mellitus using insulin therapy&#xD;
&#xD;
          -  Use of chronic hypnotic medications more than once per week or more than 5-6 times per&#xD;
             month&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jasmohan S Bajaj, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 16, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <results_first_submitted>March 2, 2021</results_first_submitted>
  <results_first_submitted_qc>March 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 29, 2021</results_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sleep</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 4, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT03091738/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ramelteon Pill</title>
          <description>Patients given ramelteon and re-evaluated after 15 days of therapy&#xD;
Ramelteon Pill: Patients with compensated cirrhosis and insomnia will be provided ramelteon</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ramelteon Pill</title>
          <description>Patients given ramelteon and re-evaluated after 15 days of therapy&#xD;
Ramelteon Pill: Patients with compensated cirrhosis and insomnia will be provided ramelteon</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sleep Quality Evaluation</title>
        <description>Pittsburgh Sleep Quality Index (PSQI) is a 19 item survey measuring 7 components of sleep. Component scores are summed to yield a global PSQI score. Scores range from 0 to 21 with higher scores indicate worse sleep quality.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ramelteon Pill</title>
            <description>Patients given ramelteon and re-evaluated after 15 days of therapy&#xD;
Ramelteon Pill: Patients with compensated cirrhosis and insomnia will be provided ramelteon</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality Evaluation</title>
          <description>Pittsburgh Sleep Quality Index (PSQI) is a 19 item survey measuring 7 components of sleep. Component scores are summed to yield a global PSQI score. Scores range from 0 to 21 with higher scores indicate worse sleep quality.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.63" spread="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.75" spread="4.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daytime Sleepiness Evaluation</title>
        <description>Epworth Sleepiness Scale asks participants to rate (on a scale of 0 to 3) their likelihood of falling asleep during 8 daily activities. Scores range from 0 to 24 with lower scores indicating less sleepiness.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ramelteon Pill</title>
            <description>Patients given ramelteon and re-evaluated after 15 days of therapy&#xD;
Ramelteon Pill: Patients with compensated cirrhosis and insomnia will be provided ramelteon</description>
          </group>
        </group_list>
        <measure>
          <title>Daytime Sleepiness Evaluation</title>
          <description>Epworth Sleepiness Scale asks participants to rate (on a scale of 0 to 3) their likelihood of falling asleep during 8 daily activities. Scores range from 0 to 24 with lower scores indicating less sleepiness.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.68" spread="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sickness Impact Profile</title>
        <description>Sickness Impact Profile is a 68 question assessment. Items are scored 0 (no) or 1 (yes). Scores range from 0 to 68 with higher numbers indicating worse quality of life.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ramelteon Pill</title>
            <description>Patients given ramelteon and re-evaluated after 15 days of therapy&#xD;
Ramelteon Pill: Patients with compensated cirrhosis and insomnia will be provided ramelteon</description>
          </group>
        </group_list>
        <measure>
          <title>Sickness Impact Profile</title>
          <description>Sickness Impact Profile is a 68 question assessment. Items are scored 0 (no) or 1 (yes). Scores range from 0 to 68 with higher numbers indicating worse quality of life.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="6.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.96" spread="7.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ramelteon Pill</title>
          <description>Patients given ramelteon and re-evaluated after 15 days of therapy&#xD;
Ramelteon Pill: Patients with compensated cirrhosis and insomnia will be provided ramelteon</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Paradoxical reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jasmohan Bajaj, MD</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>804-828-4060</phone>
      <email>jasmohan.bajaj@vcuhealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

